Covid-19 Research

Case Series

Impact of Deep Brain Stimulation on Addictive Behaviors A Case Series of Parkinsonians Patients

Journal of Biomedical Research & Environmental Sciences article abstract with citation details, DOI, publication dates, subject areas, full text links, and references.

View DOI Submit Manuscript

Article Details

Publication record, authors, dates, abstract, and full text access.

Open Access
Article Type Case Series
Subject Medicine Group
OCLC JBRES Record
de Chazeron I*, Lambert C, Brousse G, Houeto JL, Jaafari N, Rascol O, Ory Magne F, Krack P, Barroche G, Schwan R, Doe de Maindreville A, Vidailhet M, Welter M L, Lemaire JJ, Llorca PM
Issue: Volume5-Issue11
Pages: 1419-1429
Received: 2024-11-05
Accepted: 2024-11-07
Published: 2024-11-09

Abstract

Deep brain stimulation of the Subthalamic Nucleus (STN-DBS) is a recognized treatment in Parkinson’s disease (PD), but knowledge is still limited regarding its possible impact on patients with Behavioral Addiction (BA) who undergo surgery.

To assess this effect of STN-DBS, we carried out a prospective study of the follow-up of 12 PD patients with pre-existing BA (9 with pathological gambling disorder, 2 with hypersexual disorder, and 1 with compulsive shopping disorder), from 3-months pre-surgery to 12-months post-surgery, in a multicenter study. The patients were assessed for BA, mental status with anxiety, depression, mania, emotional process and for PD, using the Unified Parkinson’s Disease Rating Scale Motor Examination (UPDRS3) and cumulative daily L-Dopa Equivalent Daily Dose (LEDD). Mean 6 and 12-month post-surgery scores were compared to baseline.

After one year of STN-DBS, our results indicated that the treatment remained generally effective and stable. There was no effect on mania state or negative impact on motor signs. A significant improvement of the anxiety score was also observed.

STN is an interesting target for new therapeutic stimulation in BA and more works performed to investigate this neurobiological architecture should be performed in the future.

FullText HTML FullText PDF DOI: 10.37871/jbres2031 Crossmark

Certificate of Publication

Certificate of Publication

Copyright

© 2024 de Chazeron I, et al. Distributed under Creative Commons CC-BY 4.0 Creative CommonsAttribution

How to cite this article

de Chazeron I, Lambert C, Brousse G, Houeto JL, Jaafari N, Rascol O, Ory Magne F, Krack P, Barroche G, Schwan R, Doe de Maindreville A, Vidailhet M, Welter M L, Lemaire JJ, Llorca PM. Impact of Deep Brain Stimulation on Addictive Behaviors A Case Series of Parkinsonians Patients. J Biomed Res Environ Sci. 2024 Nov 09; 5(11): 1419-1429. doi: 10.37871/jbres2031, Article ID: JBRES2031, Available at: https://www.jelsciences.com/articles/jbres2031.pdf

Subject area(s)

PsychiatryNeurology

References

  1. Wu H, Hariz M, Visser-Vandewalle V, Zrinzo L, Coenen VA, Sheth SA, Bervoets C, Naesström M, Blomstedt P, Coyne T, Hamani C, Slavin K, Krauss JK, Kahl KG, Taira T, Zhang C, Sun B, Toda H, Schlaepfer T, Chang JW, Régis J, Schuurman R, Schulder M, Doshi P, Mosley P, Poologaindran A, Lázaro-Muñoz G, Pepper J, Schechtmann G, Fytagoridis A, Huys D, Gonçalves-Ferreira A, D'Haese PF, Neimat J, Broggi G, Vilela-Filho O, Voges J, Alkhani A, Nakajima T, Richieri R, Djurfeldt D, Fontaine P, Martinez-Alvarez R, Okamura Y, Chandler J, Watanabe K, Barcia JA, Reneses B, Lozano A, Gabriëls L, De Salles A, Halpern CH, Matthews K, Fins JJ, Nuttin B. Deep brain stimulation for refractory obsessive-compulsive disorder (OCD): emerging or established therapy? Mol Psychiatry. 2021 Jan;26(1):60-65. doi: 10.1038/s41380-020-00933-x. Epub 2020 Nov 3. PMID: 33144712; PMCID: PMC7815503.
  2. Luigjes J, van den Brink W, Feenstra M, van den Munckhof P, Schuurman PR, Schippers R, Mazaheri A, De Vries TJ, Denys D. Deep brain stimulation in addiction: a review of potential brain targets. Mol Psychiatry. 2012 Jun;17(6):572-83. doi: 10.1038/mp.2011.114. Epub 2011 Sep 20. PMID: 21931318.
  3. Wang TR, Moosa S, Dallapiazza RF, Elias WJ, Lynch WJ. Deep brain stimulation for the treatment of drug addiction. Neurosurg Focus. 2018 Aug;45(2):E11. doi: 10.3171/2018.5.FOCUS18163. PMID: 30064320; PMCID: PMC6329833.
  4. First MB. Diagnostic and statistical manual of mental disorders, 5th edition, and clinical utility. J Nerv Ment Dis. 2013 Sep;201(9):727-9. doi: 10.1097/NMD.0b013e3182a2168a. PMID: 23995026.
  5. Petry NM, Zajac K, Ginley MK. Behavioral Addictions as Mental Disorders: To Be or Not To Be? Annu Rev Clin Psychol. 2018 May 7;14:399-423. doi: 10.1146/annurev-clinpsy-032816-045120. PMID: 29734827; PMCID: PMC5992581.
  6. World Health Organisation. International statistical classification of diseases and related health problems. 2019.
  7. Kraus SW, Krueger RB, Briken P, First MB, Stein DJ, Kaplan MS, Voon V, Abdo CHN, Grant JE, Atalla E, Reed GM. Compulsive sexual behaviour disorder in the ICD-11. World Psychiatry. 2018 Feb;17(1):109-110. doi: 10.1002/wps.20499. PMID: 29352554; PMCID: PMC5775124.
  8. Protasio MI, da Silva JP, Arias-Carrión O, Nardi AE, Machado S, Cruz MS. Repetitive transcranial magnetic stimulation to treat substance use disorders and compulsive behavior. CNS Neurol Disord Drug Targets. 2015;14(3):331-40. doi: 10.2174/1871527314666150318114043. PMID: 25801835.
  9. Zucchella C, Mantovani E, Federico A, Lugoboni F, Tamburin S. Non-invasive Brain Stimulation for Gambling Disorder: A Systematic Review. Front Neurosci. 2020 Aug 18;14:729. doi: 10.3389/fnins.2020.00729. PMID: 33013280; PMCID: PMC7461832.
  10. Sakreida K, Köhler ME, Langguth B, Schecklmann M, Poeppl TB. Effect of prefrontal transcranial direct current stimulation on sexual arousal: A proof of concept study. Neurophysiol Clin. 2023 Jun;53(3):102847. doi: 10.1016/j.neucli.2023.102847. Epub 2023 Feb 23. PMID: 36841220.
  11. Lo C, Mane M, Kim JH, Berk M, Sharp RR, Lee KH, Yuen J. Treating addiction with deep brain stimulation: Ethical and legal considerations. Int J Drug Policy. 2023 Mar;113:103964. doi: 10.1016/j.drugpo.2023.103964. Epub 2023 Feb 10. PMID: 36774790; PMCID: PMC10023340.
  12. Weintraub D, David AS, Evans AH, Grant JE, Stacy M. Clinical spectrum of impulse control disorders in Parkinson's disease. Mov Disord. 2015 Feb;30(2):121-7. doi: 10.1002/mds.26016. Epub 2014 Nov 5. Erratum in: Mov Disord. 2015 Jun;30(7):1010. doi: 10.1002/mds.26254. PMID: 25370355.
  13. Ramdave S, Dawson A, Carter A, Dissanayaka NNW. Unmasking neurobiological commonalities between addictive disorders and impulse control disorders in Parkinson's disease. Brain Imaging Behav. 2020 Dec;14(6):2785-2798. doi: 10.1007/s11682-019-00041-7. PMID: 30707344.
  14. Leplow B, Renftle D, Thomas M, Michaelis K, Solbrig S, Maetzler W, Berg D, Liepelt-Scarfone I. Characteristics of behavioural addiction in Parkinson's disease patients with self-reported impulse control disorder and controls matched for levodopa equivalent dose: a matched case-control study. J Neural Transm (Vienna). 2023 Feb;130(2):125-133. doi: 10.1007/s00702-023-02588-8. Epub 2023 Jan 20. PMID: 36662280; PMCID: PMC9902415.
  15. Sauvaget A, Jiménez-Murcia S, Fernández-Aranda F, Granero R, Grall-Bronnec M, Victorri-Vigneau C, Bulteau S, Derkinderen P, Vanelle JM, Hakansson A, Mestre-Bach G, Steward T, Menchón JM. A Comparison of Treatment-Seeking Behavioral Addiction Patients with and without Parkinson's Disease. Front Psychiatry. 2017 Nov 3;8:214. doi: 10.3389/fpsyt.2017.00214. PMID: 29163234; PMCID: PMC5675875.
  16. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci. 1989 Oct;12(10):366-75. doi: 10.1016/0166-2236(89)90074-x. PMID: 2479133.
  17. Martinez-Fernandez R, Castrioto A, Krack P. Prefrontal--STN projections, the highway for emotion and cognition control. Mov Disord. 2014 Mar;29(3):305. doi: 10.1002/mds.25760. Epub 2013 Dec 20. PMID: 24375493.
  18. Mallet L, Polosan M, Jaafari N, Baup N, Welter ML, Fontaine D, du Montcel ST, Yelnik J, Chéreau I, Arbus C, Raoul S, Aouizerate B, Damier P, Chabardès S, Czernecki V, Ardouin C, Krebs MO, Bardinet E, Chaynes P, Burbaud P, Cornu P, Derost P, Bougerol T, Bataille B, Mattei V, Dormont D, Devaux B, Vérin M, Houeto JL, Pollak P, Benabid AL, Agid Y, Krack P, Millet B, Pelissolo A; STOC Study Group. Subthalamic nucleus stimulation in severe obsessive-compulsive disorder. N Engl J Med. 2008 Nov 13;359(20):2121-34. doi: 10.1056/NEJMoa0708514. Erratum in: N Engl J Med. 2009 Sep 3;361(10):1027. PMID: 19005196.
  19. Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schäfer H, Bötzel K, Daniels C, Deutschländer A, Dillmann U, Eisner W, Gruber D, Hamel W, Herzog J, Hilker R, Klebe S, Kloss M, Koy J, Krause M, Kupsch A, Lorenz D, Lorenzl S, Mehdorn HM, Moringlane JR, Oertel W, Pinsker MO, Reichmann H, Reuss A, Schneider GH, Schnitzler A, Steude U, Sturm V, Timmermann L, Tronnier V, Trottenberg T, Wojtecki L, Wolf E, Poewe W, Voges J; German Parkinson Study Group, Neurostimulation Section. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med. 2006 Aug 31;355(9):896-908. doi: 10.1056/NEJMoa060281. Erratum in: N Engl J Med. 2006 Sep 21;355(12):1289. PMID: 16943402.
  20. Broen M, Duits A, Visser-Vandewalle V, Temel Y, Winogrodzka A. Impulse control and related disorders in Parkinson's disease patients treated with bilateral subthalamic nucleus stimulation: a review. Parkinsonism Relat Disord. 2011 Jul;17(6):413-7. doi: 10.1016/j.parkreldis.2011.02.013. Epub 2011 Mar 5. PMID: 21382739.
  21. Witt K, Levin J, van Eimeren T, Hasan A, Ebersbach G; German Parkinson’s Guideline Group. Diagnostics and treatment of impulse control disorders, psychosis and delirium: systemic review-based recommendations - guideline "Parkinson's disease" of the German Society of Neurology. J Neurol. 2024 Jul 24. doi: 10.1007/s00415-024-12576-x. Epub ahead of print. PMID: 39046524.
  22. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4. doi: 10.1136/jnnp.55.3.181. PMID: 1564476; PMCID: PMC1014720.
  23. Fahn S, Elton R. Members of the UPDRS Development Committe. The Unified Parkinson’s Disease Rating Scale. 1987.
  24. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189-98. doi: 10.1016/0022-3956(75)90026-6. PMID: 1202204.
  25. Lemaire JJ, Coste J, Ouchchane L, Caire F, Nuti C, Derost P, Cristini V, Gabrillargues J, Hemm S, Durif F, Chazal J. Brain mapping in stereotactic surgery: a brief overview from the probabilistic targeting to the patient-based anatomic mapping. Neuroimage. 2007;37 Suppl 1:S109-15. doi: 10.1016/j.neuroimage.2007.05.055. Epub 2007 Jun 14. PMID: 17644002.
  26. Picillo M, Lozano AM, Kou N, Puppi Munhoz R, Fasano A. Programming Deep Brain Stimulation for Parkinson's Disease: The Toronto Western Hospital Algorithms. Brain Stimul. 2016 May-Jun;9(3):425-437. doi: 10.1016/j.brs.2016.02.004. Epub 2016 Feb 12. PMID: 26968806.
  27. Carnes P. Sexual addiction screening test. Tenn Nurse. 1991 Jun;54(3):29. PMID: 1764440.
  28. McElroy SL, Keck PE Jr, Pope HG Jr, Smith JM, Strakowski SM. Compulsive buying: a report of 20 cases. J Clin Psychiatry. 1994 Jun;55(6):242-8. PMID: 8071278.
  29. Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007 Jul;4(7):28-37. PMID: 20526405; PMCID: PMC2880930.
  30. Anton RF, Moak DH, Latham P. The Obsessive Compulsive Drinking Scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin Exp Res. 1995 Feb;19(1):92-9. doi: 10.1111/j.1530-0277.1995.tb01475.x. PMID: 7771669.
  31. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361-370. doi:10.1111/j.1600-0447.1983.tb09716.x.
  32. Montgomery SM. Depressive symptoms in acute schizophrenia. Prog Neuropsychopharmacol. 1979;3(4):429-33. doi: 10.1016/0364-7722(79)90058-4. PMID: 400999.
  33. Bech P, Bolwig TG, Kramp P, Rafaelsen OJ. The Bech-Rafaelsen Mania Scale and the Hamilton Depression Scale. Acta Psychiatr Scand. 1979 Apr;59(4):420-30. doi: 10.1111/j.1600-0447.1979.tb04484.x. PMID: 433633.
  34. Pélissolo A, Rolland JP, Perez-Diaz F, Jouvent R, Allilaire JF. Evaluation dimensionnelle des émotions en psychiatrie: validation du questionnaire Emotionnalité positive et négative à 31 items (EPN-31) [Dimensional approach of emotion in psychiatry: validation of the Positive and Negative Emotionality scale (EPN-31)]. Encephale. 2007 May-Jun;33(3 Pt 1):256-63. French. doi: 10.1016/s0013-7006(07)92037-0. PMID: 17675921.
  35. Schrag A, Barone P, Brown RG, Leentjens AF, McDonald WM, Starkstein S, Weintraub D, Poewe W, Rascol O, Sampaio C, Stebbins GT, Goetz CG. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord. 2007 Jun 15;22(8):1077-92. doi: 10.1002/mds.21333. PMID: 17394234; PMCID: PMC2040268.
  36. Castelli L, Tonello D, Rizzi L, Zibetti M, Lanotte M, Lopiano L. Alexithymia in patients with Parkinson's disease treated with DBS of the subthalamic nucleus: a case-control study. Front Psychol. 2014 Oct 13;5:1168. doi: 10.3389/fpsyg.2014.01168. PMID: 25352821; PMCID: PMC4195283.
  37. Diener E, Smith H, Fujita F. The personality structure of affect. J Pers Soc Psychol. 1995;69:130-141. doi:10.1037/0022-3514.69.1.130.
  38. Ulla M, Thobois S, Llorca PM, Derost P, Lemaire JJ, Chereau-Boudet I, de Chazeron I, Schmitt A, Ballanger B, Broussolle E, Durif F. Contact dependent reproducible hypomania induced by deep brain stimulation in Parkinson's disease: clinical, anatomical and functional imaging study. J Neurol Neurosurg Psychiatry. 2011 Jun;82(6):607-14. doi: 10.1136/jnnp.2009.199323. Epub 2010 Nov 3. PMID: 21047882.
  39. Thobois S. Proposed dose equivalence for rapid switch between dopamine receptor agonists in Parkinson's disease: a review of the literature. Clin Ther. 2006 Jan;28(1):1-12. doi: 10.1016/j.clinthera.2005.12.003. PMID: 16490575.
  40. Horváth K, Aschermann Z, Ács P, Deli G, Janszky J, Komoly S, Balázs É, Takács K, Karádi K, Kovács N. Minimal clinically important difference on the Motor Examination part of MDS-UPDRS. Parkinsonism Relat Disord. 2015 Dec;21(12):1421-6. doi: 10.1016/j.parkreldis.2015.10.006. Epub 2015 Oct 22. PMID: 26578041.
  41. Ardouin C, Chéreau I, Llorca PM, Lhommée E, Durif F, Pollak P, Krack P; groupe évaluation comportementale de la maladie de Parkinson. Evaluation des troubles comportementaux hyper- et hypodopaminergiques dans la maladie de Parkinson [Assessment of hyper- and hypodopaminergic behaviors in Parkinson's disease]. Rev Neurol (Paris). 2009 Nov;165(11):845-56. French. doi: 10.1016/j.neurol.2009.06.003. Epub 2009 Aug 15. PMID: 19683776.
  42. Kurtis MM, Rajah T, Delgado LF, Dafsari HS. The effect of deep brain stimulation on the non-motor symptoms of Parkinson's disease: a critical review of the current evidence. NPJ Parkinsons Dis. 2017 Jan 12;3:16024. doi: 10.1038/npjparkd.2016.24. PMID: 28725706; PMCID: PMC5516616.
  43. Ardouin C, Voon V, Worbe Y, Abouazar N, Czernecki V, Hosseini H, Pelissolo A, Moro E, Lhommée E, Lang AE, Agid Y, Benabid AL, Pollak P, Mallet L, Krack P. Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov Disord. 2006 Nov;21(11):1941-6. doi: 10.1002/mds.21098. PMID: 16972268.
  44. Bandini F, Primavera A, Pizzorno M, Cocito L. Using STN DBS and medication reduction as a strategy to treat pathological gambling in Parkinson's disease. Parkinsonism Relat Disord. 2007 Aug;13(6):369-71. doi: 10.1016/j.parkreldis.2006.07.011. Epub 2006 Oct 16. PMID: 17049455.
  45. Castrioto A, Funkiewiez A, Debû B, Cools R, Lhommée E, Ardouin C, Fraix V, Chabardès S, Robbins TW, Pollak P, Krack P. Iowa gambling task impairment in Parkinson's disease can be normalised by reduction of dopaminergic medication after subthalamic stimulation. J Neurol Neurosurg Psychiatry. 2015 Feb;86(2):186-90. doi: 10.1136/jnnp-2013-307146. Epub 2014 May 23. PMID: 24860137.
  46. Onder H, Comoglu S. Investigation of the nonmotor symptoms in patients with STN-DBS therapy in comparison with those without STN-DBS. J Neural Transm (Vienna). 2024 Aug;131(8):931-940. doi: 10.1007/s00702-024-02778-y. Epub 2024 Apr 30. PMID: 38684577.
  47. Voon V, Kubu C, Krack P, Houeto JL, Tröster AI. Deep brain stimulation: neuropsychological and neuropsychiatric issues. Mov Disord. 2006 Jun;21 Suppl 14:S305-27. doi: 10.1002/mds.20963. PMID: 16810676.
  48. Weintraub D, Siderowf AD, Potenza MN, Goveas J, Morales KH, Duda JE, Moberg PJ, Stern MB. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol. 2006 Jul;63(7):969-73. doi: 10.1001/archneur.63.7.969. PMID: 16831966; PMCID: PMC1761054.
  49. Gallagher DA, O'Sullivan SS, Evans AH, Lees AJ, Schrag A. Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series. Mov Disord. 2007 Sep 15;22(12):1757-63. doi: 10.1002/mds.21611. PMID: 17580327.
  50. Dodd ML, Klos KJ, Bower JH, Geda YE, Josephs KA, Ahlskog JE. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol. 2005 Sep;62(9):1377-81. doi: 10.1001/archneur.62.9.noc50009. Epub 2005 Jul 11. PMID: 16009751.
  51. Grall-Bronnec M, Sauvaget A, Perrouin F, Leboucher J, Etcheverrigaray F, Challet-Bouju G, Gaboriau L, Derkinderen P, Jolliet P, Victorri-Vigneau C. Pathological Gambling Associated With Aripiprazole or Dopamine Replacement Therapy: Do Patients Share the Same Features? A Review. J Clin Psychopharmacol. 2016 Feb;36(1):63-70. doi: 10.1097/JCP.0000000000000444. PMID: 26658263; PMCID: PMC4700874.
  52. Su ZH, Patel S, Gavine B, Buchanan T, Bogdanovic M, Sarangmat N, Green AL, Bloem BR, FitzGerald JJ, Antoniades CA. Deep Brain Stimulation and Levodopa Affect Gait Variability in Parkinson Disease Differently. Neuromodulation. 2023 Feb;26(2):382-393. doi: 10.1016/j.neurom.2022.04.035. Epub 2022 May 11. PMID: 35562261.
  53. Stefani A, Galati S, Brusa L, Pierantozzi M, Peppe A, Stanzione P. Pathological gambling from dopamine agonist and deep brain stimulation of the nucleus tegmenti pedunculopontine. BMJ Case Rep. 2010 Nov 18;2010:bcr0220102774. doi: 10.1136/bcr.02.2010.2774. PMID: 22798481; PMCID: PMC3027559.
  54. Smeding HM, Goudriaan AE, Foncke EM, Schuurman PR, Speelman JD, Schmand B. Pathological gambling after bilateral subthalamic nucleus stimulation in Parkinson disease. J Neurol Neurosurg Psychiatry. 2007 May;78(5):517-9. doi: 10.1136/jnnp.2006.102061. Epub 2007 Jan 8. PMID: 17210626; PMCID: PMC2117849.
  55. Hälbig TD, Tse W, Frisina PG, Baker BR, Hollander E, Shapiro H, Tagliati M, Koller WC, Olanow CW. Subthalamic deep brain stimulation and impulse control in Parkinson's disease. Eur J Neurol. 2009 Apr;16(4):493-7. doi: 10.1111/j.1468-1331.2008.02509.x. PMID: 19236471.
  56. Demetriades P, Rickards H, Cavanna AE. Impulse control disorders following deep brain stimulation of the subthalamic nucleus in Parkinson's disease: clinical aspects. Parkinsons Dis. 2011 Feb 20;2011:658415. doi: 10.4061/2011/658415. PMID: 21403902; PMCID: PMC3043299.
  57. Heiden P, Heinz A, Romanczuk-Seiferth N. Pathological gambling in Parkinson's disease: what are the risk factors and what is the role of impulsivity? Eur J Neurosci. 2017 Jan;45(1):67-72. doi: 10.1111/ejn.13396. Epub 2016 Oct 1. PMID: 27623191; PMCID: PMC5215459.
  58. Lee JM, Pak K. Comparison of UPDRS III score between young and late onset Parkinson disease after deep brain stimulation: A meta-analysis. Medicine (Baltimore). 2023 Nov 3;102(44):e35861. doi: 10.1097/MD.0000000000035861. PMID: 37933060; PMCID: PMC10627674.
  59. Hvingelby VS, Pavese N. Surgical Advances in Parkinson's Disease. Curr Neuropharmacol. 2024;22(6):1033-1046. doi: 10.2174/1570159X21666221121094343. PMID: 36411569; PMCID: PMC10964101.
  60. Lieberman A. Depression in Parkinson’s disease -- a review. Acta Neurol Scand. 2006;113(1):1-8. doi:10.1111/j.1600-0404.2006.00536.x.
  61. Dulski J, Schinwelski M, Konkel A, Grabowski K, Libionka W, Wąż P, Sitek EJ, Sławek J. The impact of subthalamic deep brain stimulation on sleep and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord. 2019 Jul;64:138-144. doi: 10.1016/j.parkreldis.2019.04.001. Epub 2019 Apr 5. PMID: 30975618.
  62. Hogg E, Wertheimer J, Graner S, Tagliati M. Deep Brain Stimulation and Nonmotor Symptoms. Int Rev Neurobiol. 2017;134:1045-1089. doi: 10.1016/bs.irn.2017.05.022.
  63. Bucur M, Papagno C. Deep Brain Stimulation in Parkinson Disease: A Meta-analysis of the Long-term Neuropsychological Outcomes. Neuropsychol Rev. 2023 Jun;33(2):307-346. doi: 10.1007/s11065-022-09540-9. Epub 2022 Mar 23. PMID: 35318587; PMCID: PMC10148791.
  64. Aviles-Olmos I, Kefalopoulou Z, Tripoliti E, Candelario J, Akram H, Martinez-Torres I, Jahanshahi M, Foltynie T, Hariz M, Zrinzo L, Limousin P. Long-term outcome of subthalamic nucleus deep brain stimulation for Parkinson's disease using an MRI-guided and MRI-verified approach. J Neurol Neurosurg Psychiatry. 2014 Dec;85(12):1419-25. doi: 10.1136/jnnp-2013-306907. Epub 2014 Apr 29. PMID: 24790212; PMCID: PMC4451170.
  65. Pelissolo A. [Balance émotionnelle dans les troubles anxieux et dépressifs]. 2011;169(2):124-127. doi: 10.1016/j.amp.2010.12.005.
  66. Degoulet M, Tiran-Cappello A, Combrisson E, Baunez C, Pelloux Y. Subthalamic low-frequency oscillations predict vulnerability to cocaine addiction. Proc Natl Acad Sci U S A. 2021 Apr 6;118(14):e2024121118. doi: 10.1073/pnas.2024121118. PMID: 33785599; PMCID: PMC8040637.
Publish with JBRES — Peer-reviewed, multidisciplinary Open Access with rapid review, DOI, and global visibility.
Double-Blind CrossRef DOI Discoverable
Submit Manuscript Membership